阿达利穆马布单疗法与阿达利穆马布与甲索酸治疗牛皮
Zenas Z N Yiu1,2, Catherine H Smith3, Philip Laws4
1Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
JAMA dermatology
|June 4, 2025
概括
添加甲铁沙酸到阿达利木马布并没有提高其在斑块性牛皮患者的有效性或持久性. 这项研究发现单疗法和组合疗法之间的药物存活率或牛皮区域和严重性指数得分没有显著差异.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮是一种慢性自身免疫性疾病,影响皮肤.
- 阿达利穆马布是一种适度至重症牛皮的生物疗法.
- 同时使用甲状腺素和阿达利穆马布治疗牛皮的作用尚不清楚.
研究的目的:
- 评估在斑块性牛皮患者中,阿达利穆马布单一治疗与阿达利穆马布与甲状腺素合并疗法的有效性和持续性.
- 为了比较两组治疗组之间的药物存活率,牛皮区域和严重性指数 (PASI75) 评分和安全性概况.
主要方法:
- 使用生物制剂和免疫调节剂注册 (2007-2021) 的目标试验仿真队列研究.
- 与阿达利穆马布单疗法 (40毫克每隔一周) 与阿达利穆马布加上甲状腺素 (每周一次) 的比较.
- 使用加权回归模型分析了1年和3年的药物存活率,1年和3年的PASI75,严重不良事件以及药物度/抗体.
主要成果:
- 在1年后的阿达利穆马布药物存活率没有显著差异 (78.1%与79.1%).
- 在1年 (52.0%对49.4%) 或3年 (32.4%对37.2%) 的PASI75成就中没有显著差异.
- 严重不良事件的发生率相似;在联合治疗中观察到较低的抗药抗体水平.
结论:
- 同时服用甲状腺素似乎不会提高在斑块性牛皮中阿达利穆马布的有效性或持续性.
- 单一治疗的阿达利穆马布在疗效和安全性方面表现出与组合治疗相似的结果.
- 进一步的研究可能会探索特定的患者亚组或替代组合策略.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
01:17Phase II Reactions: Methylation Reactions
373
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
373
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
01:28Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
01:29Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244